Anti-oxidant and pro-oxidant behaviour of bucillamine.
Bucillamine (BUC) is used clinically for the treatment of rheumatoid arthritis. Some of the pharmacological action of BUC has been reported as being dependent on the production of reactive oxygen species (ROS). In this paper the reactivity of BUC with superoxide anion radical (O(2) (*-)) generated from potassium superoxide/18-crown-6 ether dissolved in DMSO, hydroxyl radical (HO(*)) produced in the Cu(2+)-H(2)O(2) reaction, peroxyl radical (ROO(*)) from 2,2'-azobis (2-amidino-propane) dichloride decomposition, and singlet oxygen ((1)O(2)) from a mixture of alkaline aqueous H(2)O(2) and acetonitrile, have been investigated. Chemiluminescence, fluorescence, electron paramagnetic resonance (EPR) spin-trapping techniques and the deoxyribose and oxygen radical absorbance capacity towards ROO(*) (ORAC(ROO)) assays were used to elucidate the anti- and pro-oxidative behaviours of BUC towards ROS. The results indicated that BUC efficiently inhibited chemiluminescence from the O(2) (*-)-generating system at relatively high concentrations (0.5-2 mmol/L); however, at lower concentrations (<0.5 mmol/L) the drug enhanced light emission. The behaviour of BUC was correlated with a capacity to decrease the chemiluminescence signal from the Cu(2+)-H(2)O(2) system; scavenging HO(*) was effective only at high concentrations (1-2 mmol/L) of the drug. Bucillamine also prevented deoxyribose degradation induced by HO(*) in a dose-dependent manner, reaching maximal inhibition (24.5%) at a relative high concentration (1.54 mmol/L). Moreover, BUC reacts with ROO(*); the relative ORAC(ROO) was found to be 0.34 micromol/L Trolox equivalents/micromol sample. The drug showed quenching of (1)O(2)-dependent 2,2,6,6-tetramethylpiperidine-N-oxide radical formation from 2,2,6,6-tetramethyl-piperidine (e.g. 90% inhibition was found at 1 mmol/L concentration). The results showed that BUC may directly scavenge ROS or inhibit reactions generating them. However, the drug may have pro-oxidant activity under some reaction conditions.
Kładna
Aleksandra
A
Department of Medical History and Ethics, Pomeranian Medical Academy, Rybacka 1, 70-204 Szczecin, Poland.
Aboul-Enein
Hassan Y
HY
Kruk
Irena
I
Michalska
Teresa
T
Lichszteld
Krzysztof
K
D000838:Anions / Q000138:chemical synthesis / Q000737:chemistry; D000975:Antioxidants / Q000737:chemistry*; D003545:Cysteine / Q000031:analogs & derivatives* / Q000737:chemistry; D016166:Free Radical Scavengers / Q000737:chemistry; D005609:Free Radicals / Q000138:chemical synthesis / Q000737:chemistry; D008163:Luminescent Measurements / Q000379:methods*; D015394:Molecular Structure; D016877:Oxidants / Q000737:chemistry*; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000138:chemical synthesis / Q000737:chemistry; D012680:Sensitivity and Specificity; D026082:Singlet Oxygen / Q000737:chemistry; D013481:Superoxides / Q000138:chemical synthesis / Q000737:chemistry; D013997:Time Factors
D000838:Anions; D000975:Antioxidants; D016166:Free Radical Scavengers; D005609:Free Radicals; D016877:Oxidants; D017382:Reactive Oxygen Species; D013481:Superoxides; D026082:Singlet Oxygen; D003545:Cysteine; C026535:bucillamine